The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1662
October 31, 2022
View Complete Issue         Table of Contents 2019 
Two Vonoprazan Combinations (Voquezna) for H. pylori
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Two Vonoprazan Combinations (Voquezna) for H. pylori
October 31, 2022 (Issue: 1662)
The FDA has approved vonoprazan, a potassium-competitive acid blocker, copackaged with amoxicillin (Voquezna Dual Pak – Phathom) and with amoxicillin and clarithromycin (Voquezna Triple Pak) for treatment of Helicobacter pylori infection in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Two Vonoprazan Combinations (Voquezna) for H. pylori
Article code: 1662a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.